Published 2025-01-01
“…Yi Liu,1– 4,* Xiao Wang,1– 3,5,* Ni Zhang,1– 4,* Simin He,1– 4 Jianping Zhang,1– 4 Xiaoping Xu,1– 4 Shaoli Song1– 4 1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Center for Biomedical Imaging, Fudan University, Shanghai, 200032, People’s Republic of China; 4Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, People’s Republic of China; 5State Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory & Center for Molecular Imaging and
Translational Medicine, School of Public Health, Shenzhen Research Institute of Xiamen University, Xiamen University, Xiamen, 361102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shaoli Song; Xiaoping Xu, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China, Email shaoli-song@163.com; xxp0012@ustc.eduPurpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. …”
Get full text
Article
